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Abstract
Whether a repeat renal biopsy is helpful during lupus nephritis (LN) flares remains debatable. In order to analyze the clinical utility of
repeat renal biopsy in this complex situation, we retrospectively reviewed our series of 54 LN patients who had one or more repeat
biopsies performed only on clinical indications. Additionally, we reviewed 686 well-documented similar cases previously reported
(PubMed 1990–2015).
The analysis of all patients reviewed showed that histological transformations are common during a LN flare, ranging from 40% to
76% of cases. However, the prevalence of transformations and the clinical value of repeat biopsy vary when they are analyzed
according to proliferative or nonproliferative lesions.
The great majority of patients with class II (78% in our series and 77.5% in the literature review) progressed to a higher grade of
nephritis (classes III, IV, or V), resulting in worse renal prognosis. The frequency of pathological conversion in class V is lower (33% and
43%, respectively) but equally clinically relevant, since almost all cases switched to a proliferative class. Therefore, repeat biopsy is
highly advisable in patients with nonproliferative LN at baseline biopsy, because these patients have a reasonable likelihood of switch
to a proliferative LN that may require more aggressive immunosuppression.
In contrast, the majority of patients (82% and 73%) with proliferative classes in the reference biopsy (III, IV or mixed III/IV+V),
remained into proliferative classes on repeat biopsy. Although rebiopsy in this group does not seem as necessary, it is still advisable
since it will allow us to identify the 18% to 20% of patients that switch to a nonproliferative class. In addition, consistent with the
reported clinical experience, repeat biopsy might also be helpful to identify selected cases with clear progression of proliferative
lesions despite the initial treatment, for whom it is advisable to intensify inmunosuppression. Thus, our experience and the literature
data support that repeat biopsy also brings more advantges than threats in this group.
The results of the repeat biopsy led to a change in the immunosuppresive treatment in more than half of the patients on average,
intensifying it in the majority of the cases, but also reducing it in 5% to 30%.
Abbreviations: anti-dsDNA = anti-dsDNA antibodies, ISN/RPS = International Society of Nephrology/Renal Pathology Society,
LN = lupus nephritis, SD = standard deviation, SLE = systemic lupus erythematosus.
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Lupus nephritis (LN) remains a common complication and major
determinant of outcome in systemic lupus erythematosus (SLE).
Today, a baseline renal biopsy is highly recommended for all
subjects with suspected LN. Biopsy allows the clinician to
recognize and classify the type of renal involvement, assess its
activity, and thus guide the intensity of treatment.[1,2]
LN flares represent a significant problem because of the
potential for cumulative damage that may lead to deterioration of
renal function evenafter a successful treatment.[3]Thepathological
class of LN may change to a different class during a disease
flare.[2,3] Therefore, repeat renal biopsy has attracted much
attention and its clinical relevance has been evaluated by a number
of studies. However, whether a repeat renal biopsy is helpful in
patientswith suspicion of renalflare remains debatable, since some
authors have proposed that patients with proliferative lesions on
their original biopsy rarely switch to a pure nonproliferative
nephritis during a flare and, in these cases, appropriate treatment
adjustments can be based only on clinical and biologic signs and
symptoms without additional biopsy.[2–6] This approach is
reinforced because clinical studies support that mycophenolate
mofetil with glucocorticosteroids can be used for induction and
maintenance treatment in all of the serious forms of LN (class III,
IV, and V), thus making it possible to eliminate the need to
differentiate between each histological class of LN.[2–6]
In the present study, we retrospectively reviewed our series of
LN patients who had one or more repeat renal biopsies perfomed
only based on clinical indications in order to assess the rate of
pathological class transformation and the changes in the intensity
of treatment decided based on the results of the repeat biopsy.
Whether repeat renal biopsies have a prognostic value was not
addressed in the present study. Current evidence of the value of
repeat renal biopsy in this complex situation is also analyzed
through a systematic review of the English-language literature,
based on a PubMed search.2. Methods
2.1. Patient selection
The sample consised of 429 patients with SLE (from Internal
Medicine, Nephrology, and Rheumatology departments; all
fulfilling the American College of Rheumatology classification
criteria)[7] treated between 1988 and 2014 at the Hospital
Universitario de Bellvitge (Barcelona, Spain), a referral tertiary
care hospital that does not attend to pediatric populations.
Patients were registered in a specific database (ACHILLES
project).
From a total of 190 patients with LN, we selected for analysis
54 patients with 2 or more renal biopsies. Renal biopsy was
repeated only on the basis of one of these clinical indications:
increase, persistence, or recurrence of proteinuria, nephrotic
syndrome, or active urinary sediment (hematuria and/or cellular
casts), or increase in serum creatinine level or unexplained
progression to renal failure. This study did not include patients
with protocol biopsies performed to evaluate the response to
therapy.
Medical records were reviewed, and clinical, laboratory, and
treatment data were obtained from each patient. Data were
collected retrospectively. Laboratory values, such as serum
creatinine, albumin, urea, proteinuria, complement levels (C3
and C4), and antidouble-stranded DNA antibody (anti-dsDNA)
titer, were selected during the 3 months before and the month2
after the renal biopsy was performed. Anti-dsDNA antibodies
were determined using both fluorescence enzyme immunoassay
(FEIA) and immunofluorescence on Crithidia luciliae.
Treatment regimenswere determined by the referring physician.
Treatments more frequently used for induction in proliferative
classes were cyclophosphamide, azathioprine, or mycophenolate.
For maintenance, the more frequently used drugs were mycophe-
nolate or azathioprine. We considered a treatment change when
the immunosuppressive treatment was modified after the renal
biopsy (drug change, drug addition, or drug suspension).
In accordance with the guidelines of our institutional ethics
committee, formal approval for this study was not required. The
local ethics committee agreed that the findings in this report were
based on normal clinical practice and were therefore suitable for
dissemination. Informed consent was not obtained from the
patients, but their clinical records and information were
anonymized before analysis. This study was conducted in
accordance with the principles of the Declaration of Helsinki
and the International Conference for Harmonization.2.2. Renal biopsies
All biopsies were assessed by experienced pathologists by light
microscopy and immunofluorescence. Renal biopsy was evaluat-
ed according to the WHO classification of LN when the biopsy
was performed before the year 2003, and according to the
International Society of Nephrology/Renal Pathology Society
(ISN/RPS) classification of LN after that date. If biopsy specimens
were classified according to World Health Organization
classification, they were reassessed according to the ISN/RPS
classifications. ISN/RPS classifications between the first and the
second biopsy examinations were compared. If patients hadmore
than 2 biopsies, the second and third, as well as third and fourth,
biopsies were paired. Thus, the last biopsy performed before the
repeat biopsy served as the reference biopsy.
Activity and chronicity indices were scored according to the
1983 proposal by Austin et al.[8] Class III, class IV, and
combinations of III/IV plus V were considered proliferative
classes. All of the rest were considered nonproliferative.2.3. Literature search strategy and selection criteria
In addition to our case series, we analyzed current evidence of the
value of repeat renal biopsy in cases of suspicion of renal flare
using a systematic review of reports published in indexed
international journals (excluding reviews, congress abstracts, or
unpublished results). Searches were conducted in the PubMed
database (i.e., including MEDLINE, National Library of
Medicine, and PubMed Central) for the period between January
1990 and December 2015 using the strategies recommended by
the Cochrane handbook. Search terms included “Systemic lupus
erythematosus,” “lupus nephritis,” “repeat renal biopsy,”
“second renal biopsy,” and “serial renal biopsy.” Only
English-language reports were selected for review. To standardize
the information, we excluded patients aged less than 18 years.
The references of the studies obtained were also examined to
identify additional reports.2.4. Statistical analysis
Statistical analysis was performed using SAS version 9.1.3
(SAS, Inc., Cary, NC). Qualitative variables were described by
frequencies and percentages, and quantitative variables were
Table 1
Main clinical and laboratory data of our 54 patients with at least 2 renal biopsies.
1st Biopsy 2nd Biopsy P
Serum creatinine, mmol/L 84.4±24.9 114.3±197.9 .108
Proteinuria, g/d 2.9±3.7 3.3±3 .203
Microhematuria 29 (54%) 24 (44%) d=9.26 (95% CI –9.32, 26.97), P= .197
Urinary casts 10 (19%) 7 (13%) d=5.56 (95% CI –8.5,19.5), P= .459
Positive anti-DNAn 45 (83%) 40 (74%) d=9.26 (95% CI –6.29, 24.34), P= .049
C3 low, n (%) 38 (70%) 28 (52%) d=18.52 (95% CI 0.16, 35.22), P= .048
C4 low, n (%) 38 (70%) 24 (44%) d=25.93 (95% CI 7.27, 42.20), P= .02
Arterial hypertension 17 (31%) 17 (31%) d=0 (95% CI –17.10, 17.10), P= .866
Nephrotic range proteinuria 19 (35%) 23 (43%) d=–7.41 (95% CI –24.86, 10.70), P= .462
Progression to renal failure 11 (20%) 15 (28%) d=–7.41, (95% CI –23.09, 8.73), P= .368
Renal histology
I 1
II 9 (17%) 2
III 8 (15%) 8
IV 28 (52%) 29
V 6 (11%) 12
Mixed (III/V+V) 3 (5%) 2
Activity index 7.9±4.7 6.6±5.3 .215
Chronicity index 1.1±1.5 2.2±2 .003
Narváez et al. Medicine (2017) 96:24 www.md-journal.comdescribed by mean or median± standard deviation (SD) and
range. Continuous variables were compared using the Student
t test or median test. Categorical variables were analyzed using
the Chi-squared test or Fisher exact test when the expected values
were less than 5, and by calculating the 95% confidence intervals
(CIs) for the differences between proportions using Newcomb
method. A multivariate logistic regression analysis was per-
formed to identify clinical predictors of pathological class
transformation. The construction of the regression model was
perfomed by backward stepwise using both statistical and clinical
judgment. Statistical significance was defined as P .05.3. Results
We identified 54 lupus patients with at least two renal biopsies.
These patients had a total of 125 renal biopsies: 38 patients had
2 biopsies, 15 had 3, and 1 patient had 4 biopsies. Of the
54 patients, 49 were women (91%) and 5 (9%) were men, with
a mean age at the time of first biopsy of 45±11 years. The
median disease duration at the time of the second biopsies was
48±9 months. The average interval between the first and second
biopsy was 24±16 months.
Their main laboratory data at the time of the first and second
renal biopsies are summarized in Table 1. Clinical indications
for biopsies were the increase, persistence, or recurrence of
proteinuria, nephrotic syndrome, or active urinary sediment in 39Table 2
Changes in nephritis classification (ISN/RPS) from the first to
second biopsies in our 54 patients.
Repeat Reference Biopsy
biopsy II III IV V Mixed III/IV+V
I 1
II 1 1
III 2 2 4
IV 3 4 21 1
V 2 2 1 4 3
Mixed III/IV+V 1 1
ISN/RPS= International Society of Nephrology/Renal Pathology Society.
3
patients (72%), and increase in serum creatinine or unexplained
progression to renal failure in 15 (28%). Regarding histopatho-
logical analysis, proliferative classes (class III, IV, or a
combination of III/IV+V) were the most frequent (72%),
followed by class II (15%).3.1. Pathological transition
The distribution of the ISN/RPS classes at first and second renal
biopsies (N=108), and the transitions from one class to the other
are shown in Table 2.
Of the 54 repeat biopsies, class switches occurred in 27 (50%)
patients. When the first biopsies were proliferative classes (III, IV,
or a combination of III/IV+V) (n=39), histological change
occurred in 41% of cases (16/39), but only 18% of them changed
to a nonproliferative class, usually to a class V (only 1 case
improved to a class II). The rest remained in the proliferative class
on the repeat biopsy, although the transitions from class III to
class IV or vice versa, or the switch from a mixed class to pure
class III or IV or vice versa were common.
Among nonproliferative classes, the great majority of patients
with class II (7/9; 78%) showed transformation to a higher grade
of nephritis (class III or IV in 5 cases and class V in the other 2),
resulting in worse renal prognosis. Histological change occurred
less frequently in patients with class V (2/6; 33%), but all cases
switched to a proliferative class. Globally, pathological class
transformation during nephritic flares were more frequent in
patients with nonproliferative lesions (classes II and V: 10/15;
67%) than in those with proliferative lesions (classes III and IV:
13/36; 36%) in their reference biopsy (P< .004).
Table 1 also shows the results of the comparative study of the
main clinical and laboratory data of the 54 patients at the time of
the first and second biopsies. In the baseline renal biopsy, patients
had higher immunological (positive anti-DNAn antibodies and
hypocomplementemia) and histological activity (7.9±4.7 vs 6.6
±5.3; P= .215). As expected, the mean chronicity index in the
second biopsies was significantly higher (2.2±2 vs 1.1±1.5;
P= .003). In the multivariate logistic regression analysis, no
clinical predictor of pathological class transformation could be
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4
age, duration of SLE, baseline renal function, proteinura,
microhematuria, casts, immunological activity defined as positive
anti-DNAn antibodies and/or hypocomplementemia, and histo-
logical activity and chronicity indices; details not shown).
After the repeat biopsy, 17 (31%) patients had a change of
treatment regimen: 15 (28%) received an increase in immuno-
suppression; while in 2 (4%) cases, immunosuppressive therapy
was decreased (dose) or stopped.3.2. Patients with more than 2 biopsies
Fifteen of the 54 patients had a third renal biopsy and 1 had a
fourth biopsy. Pathological class transformation occurred in
56% (9/16) of these cases. Among the 15 patients with a third
biopsy, class switches occurred in 8 (53%): 2 patients with class II
progressed to a proliferative class, 2 with class III changed to class
IV, 2 with class IV changed to class V, 1 with class V changed to
class IV, and 1 with class V progressed to class VI. The only
patient who had a fourth biopsy also switched from class IV to
mixed class IV+V.3.3. Literature review
The MEDLINE search resulted in 70 articles. After evaluation of
the full text, 36 of these articles were excluded: 6 corresponded to
pediatric cases[9–14]; 6 were a review or an editorial[2,15–19]; 11
corresponded to case reports[20–30]; 12 were studies with not
relevant data or that analyzed a different issue[31–42]; and 1 was
excluded due to duplicate/multiple publication.[43] In addition,
we excluded 22 studies[44–65] in which the repeat biopsy was done
after induction or maintenance therapy to determine the effect of
treatment on kidney histology (protocol biopsy), and 2 studies
because their clinical characteristics were not sufficiently detailed
to be individually analyzed.[66,67]
Therefore, 10 articles were finally selected for review,[2,68–76]
identifying 686 well-documented cases of patients with repeat
biopsy performed only based on clinical indications (increase,
persistence, or recurrence of proteinuria, nephrotic syndrome,
or active urinary sediment; increase in serum creatinine or
unexplained progression to renal failure; suspicion of renal flare
or class change, or refractoriness to standard therapy). The main
characteristics of these 10 series are summarized in Table 3. The
rate of pathological class transformation in these studies ranged
from 40% to 76% of cases (mean 53%). The results of the repeat
biopsy led to a change in the immunosuppressive treatment in
18% to 79% of the patients (mean 57% of cases), intensifying it
in the majority of the cases (between 18% and 60.5%; mean
39%), but also reducing it in 5% to 30%.
The distributions of the ISN/RPS classes at initial and repeat
renal biopsies are shown in Table 4. The transitions from one
class to the other are shown in Table 5; due to the low number of
cases with classes I or VI in the reference biopsy, they were
excluded from the table.
Similar to our results, most patients with class II (77.5%)
progressed to a higher grade of nephritis (proliferative classes III,
IV, or mixed in 63% of cases, class V in 13.5%, and class VI in
1%), resulting in worse renal prognosis. When previous biopsy
showed class V, transition to other classes occurred less
frequently (43%) and changes were also in almost cases
(40%) into proliferative classes.
By contrast, most patients (351/484; 73%) with proliferative
classes in the reference biopsy (III, IV, or mixed III/IV+V)
remained in the proliferative class on the repeat biopsy (although
Table 4
Distribution of the ISN/RPS classes at the first and repeat renal
biopsies in 686 well-documented published cases of patients with
repeat biopsy performed only on clinical indications.
Repeat biopsy
Reference biopsy
I II III IV V VI
I 2 3 0 1 0 0
II 1 15 8 40 2 0
III 0 13 26 25 4 0
IV 0 29 34 158 13 0
V 1 11 9 37 62 1
VI 0 1 1 15 1 2
Mixed II +V 0 0 0 2 1 0
Mixed III +V 0 6 7 21 19 0




I 0 0 0
II 0 0 2
III 0 1 4
IV 0 12 9
V 0 8 9
VI 0 0 1
II+V 1 0 0
III +V 1 17 8
IV+V 0 5 11
ISN/RPS= International Society of Nephrology/Renal Pathology Society.
Narváez et al. Medicine (2017) 96:24 www.md-journal.comthe transitions from class III to class IV or vice versa, or the switch
from a mixed class to pure class III or IV or vice versa were
common). Since biopsies were performed only based on clinical
indications, in those cases who switched to a nonproliferativeTable 5
Transitions from one class to other in 676 well-documented publishe
indications.
∗
Reference biopsy Repeat biopsy
Class II mesangial LN (N=81) 4% (3/81) switched to class I
18.5% (15/81) no shift in pathological cl
77.5% (63/81) switched to higher grade
13.5% (11/81) switched to class V; 1
Proliferative classes (pure class III focal LN
and class IV diffuse LN) (N=397)
28.5% (113/397) transformed to nonprol
switched to classes V or VI; 0.5% (2/3
61% (243/397) remained in pure prolifer
class IV switched to class III)
10.5% (41/397) transformed to mixed cl
Mixed classes III +V and IV+V (N=87) 2% (2/87) switched to class II
21% (18/87) switched to classes V or VI
77% (67/87) remained in the same mixe
Pure class V mesangial LN (N=111) 2% (2/111) switched to class II and 1%
56% (62/111) no shift in pathological cla
40% (45/111) transformed to proliferative
1% (1/111) progressed to class VI
LN= lupus nephritis.
∗
Due to the low number of cases with classes I or VI in the reference biopsy, they were excluded in t
5
class (133/484; 27%), the progression to a class V or VI wasmore
frequent (82/484; 17%) than the improvement to a classes I or II
(51/484; 11%).4. Discussion
Relapses occur between 27% and 66% in patients with
LN,[3–6,68–76] even after an initial complete remission. LN flares
represent a significant problem because of the potential for
cumulative damage that may lead to deterioration of renal
function as well as toxicity due to additional immunosuppres-
sion.[3] Histological transformation from one class to another
during a LN flare is very well recognized,[68–76] and there is
evidence showing that relapsing nephritis has a worse renal
prognosis.[2,3] In this clinical scenario, the usefulness of repeat
renal biopsy is a controversial issue, for 2 reasons: the doubts
about its influence on patient’s management and the risk of
possible complications, mainly related to bleeding. Considering
the risk-benefit ratio, some authors are reluctant to repeat
biopsies since there is no clear evidence in which patients
undergoing a second biopsy will have clear therapeutic
consequences that justify its risk.[2–6]
To determine the role of repeat biopsies, this study investigated
how often a clinically relevant switch occurred when repeat
biopsies were performed for renal flares. The results of our series,
as well as the literature review, confirm that histological
transformation is very prevalent during an LN flare, ranging
from 40% to 76%of cases,[68–76] and supports the usefulness of a
repeat biopsy in guiding treatment of LN flares, both to identify
those patients for whom it is necessary to intensify immunosup-
pression therapy and to avoid unnecessary increased immuno-
suppression therapy in others.[4,68,70,71,73–75] However, the
frequency of histological transformation and the clinical valued cases of patients with repeat biopsy performed only on clinical
ass
nephritis: 63% (51/81) transformed to proliferative classes (III, IV, III +V, IV+V);
% (1/81) switches to class VI
iferative classes (I, II, V, VI): 12% (49/397) switched to classes I or II; 16% (62/397)
97) switched to class II+V
ative classes (39% of class III patients‘ switched to class IV and 8% of patients in
asses: 7% (28/397) switched to class III +V; 3.5% (13/397) switched to class IV+V
d class or were reclassified into pure class III or IV
(1/111) switched to class II+V
ss
classes (III, IV, III +V, IV+V)
he table.
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initial biopsy.
Current evidence demonstrates that histological transforma-
tion is common in nonproliferative lesions. The great majority
of patients with class II (78% in our series and 77.5% in the
literature revision) progressed to a higher grade of nephritis,
resulting in worse renal prognosis. Most of these patients
progressed to a proliferative class (III, IV, or a combination of
III/IV+V), and less frequently to a class V.
The frequency of pathological conversion in class V is lower
(33% in our series and 43% in the literature) but equally
clinically relevant, since in almost all cases these patients switched
to a proliferative class. Therefore, nonproliferative II or V LN
class diagnosed at baseline biopsy can benefit from a repeat
biopsy, because these patients have a reasonable possibility of
switching to a proliferative LN that may require more aggressive
immunosuppression.
In contrast, the great majority of patients (82% in our series
and 73% in the literature revision) with proliferative classes in the
reference biopsy (III, IV, or mixed III/IV+V), remained into
proliferative class on the repeat biopsy, although the transition
from class III to class IV or vice versa, or the switch from a mixed
class to pure class III or IV or vice versa, were common.
Theoretically, the detection of these transformations within the
proliferative group generally does not have clear therapeutic
consequences, since treatment guidelines usually do not differen-
tiate between classes III and IV nephritis.[1,3,5] Similarly, the
addition or disappearance of class V lesions on a second biopsy
next to persisting proliferative lesions should not significantly
influence treatment choices, since the prognosis is largely
determined by the associated proliferative lesions.[1,3,5] However,
data from the literature do not seem to confirm this
approach.[4,68,70,71,74,75] Although the proliferative classes were
the majority in the reference biopsy in nearly all of the reviewed
series (484/676; 72%), the results of the repeat biopsy led to a
change in the immunosuppressive treatment in 18% to 79% of
the patients (mean 57%of cases), intensifying it in the majority of
the cases (between 18% and 60.5%; mean 39%). These data
suggest that in daily clinical practice, in some cases with clear
progression of proliferative lesions in the second biopsy despite
the initial treatment, the immunosuppressive treatment was
intensified to avoid the progression of renal damage and the
development of sclerosing lesions. Another important question to
consider when deciding if it is worthwhile to rebiopsy this group
of patients is that a considerable percentage of cases (18% in
our series and 27% in the literature review) switched to a
nonproliferative class, being much more frequent the progression
to a class V or VI, than the improvement to a classes I or II. The
switch from proliferative to nonproliferative lesions has clear
therapeutic consequences that justify performing a repeat biopsy.
Noclinical or biochemical predictor of transformationhave been
identified.[71,72] In diffuse proliferative lupus nephropathy, some
histological parameters at the initial biopsy (higher glomerular
activity and larger interstitial volume density) can predict the
progression of renal pathology or function at the second biopsy.[77]
Whether repeat renal biopsies have a prognostic value was not
addressed in the present study. Although the immediate clinical
relevance of the serial renal biopsymay be limited, repeat biopsies
could have a prognostic value. Recently, Arriens et al have
demonstrated that a repeat renal biopsy demonstrating histo-
pathologic worsening and a short time between biopsies is
associated with significantly increased risk for end-stage renal
disease and death.[78] Only 2 known studies investigated the6
prognostic value of repeat biopsies in the face of a LN flare and
both report a predictive association of high chronic index scores
and poor renal outcome.[75,76] In addition, having a higher serum
creatinine and a high activity index at the second biopsy was also
associated with a worse renal prognosis.[63,68,75,76]
When interpreting the results of our study, one needs to
consider the potential limitations derived from its retrospective
nature and the small sample size. Not all of the biopsies were
evaluated with activity and chronicity indices, and they were
evaluated by different pathologists with different classifications
according to the year when they were performed, as mentioned.
In addition, we cannot ignore the pitfalls inherent in any
systematic review, including the relatively small number of
identified patients, the retrospective design, and incomplete
follow-up data in some cases.
In conclusion, histological transformations are common
during a LN flare, and they occurred when the previous biopsy
had nonproliferative lesions as well as when lesions were
proliferative. However, the prevalence of transitions varied when
they were analyzed according to proliferative or nonproliferative
lesions. In cases of a nonproliferative lesion in the reference
biopsy (classes II or V), switches to a proliferative class are
frequently found and repeat biopsy is highly advisable. In most
but not all cases with originally proliferative LN, the repeat
biopsy confirmed ongoing or recurrent proliferative LN.
Although rebiopsy in this group does not seem as necessary, it
is also advisable since it will allow us to identify the 18% to 20%
of patients that switch to a nonproliferative class. In addition,
consistent with the reported clinical experience, repeat biopsy
might also be helpful to identify selected cases with clear
progression of proliferative lesions despite the initial treatment,
for whom it is advisable to intensify immunosuppression. Thus,
our experience and the literature data support that repeat biopsy
also brings more advantages than threats in this group.
Although there is still a need for new randomized, prospective
studies to confirm clinical observations, in daily practice kidney
repeat biopsies are useful in guiding treatment of LN flares. The
results of the repeat biopsy led to a change in the immunosup-
pressive treatment in more than half of the patients on average,
leading to not only its intensification in the majority of the cases,
but also its reduction in 5% to 30%References
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